

**Biological Basis for Co-Occurrence of Substance Abuse
and Other Psychiatric Disorders**

**Bethesda North Marriott Hotel & Conference Center
Bethesda, Maryland
April 10–11, 2006**

Agenda

Monday, April 10, 2006

8:30 – 8:45 a.m.

WELCOME AND OVERVIEW OF THE WORKSHOP GOALS

Welcome: *Paul Schnur, Ph.D., Deputy Director, National Institute on Drug Abuse*

Overview: *Susan Volman, Ph.D., National Institute on Drug Abuse,
Jerry Frankenheim, Ph.D., National Institute on Drug Abuse
Harold W. Gordon, Ph.D., National Institute on Drug Abuse*

PANEL FORMAT

In each of three panels, panelists will introduce their area of expertise and will present one or two important findings from their own or others' research that bear on the discussion topic (**a maximum of 10 minutes each**). These findings will be the basis of a discussion, with the goal of developing a research agenda to study comorbidity.

8:45 – 10:45 a.m.

PANEL 1

Develop a blueprint for human experimental research to study the biological basis of comorbidity. Discuss the advantages and limitations.

Moderator: *Harold W. Gordon, Ph.D., National Institute on Drug Abuse*

Panelists: *Kathleen T. Brady, M.D., Ph.D., Medical University of South Carolina
Tony George, M.D., Yale University School of Medicine
Bryon Adinoff, M.D., University of Texas Southwestern Medical Center
Frances R. Levin, M.D., Columbia University
Alan I. Green, M.D., Dartmouth Medical School*

10:45 – 11:00 a.m.

Break

11:00 a.m. – 12:30 p.m.

PANEL 1 (continued)

Listing and prioritizing areas of needed research

12:30 – 1:45 p.m.

Lunch (on your own)

1:45 – 3:30 p.m.

PANEL 2

Develop a blueprint for neurobiological and behavioral research in animal models to study comorbidity. Discuss the advantages and limitations.

Moderator: *Jerry Frankenheim, Ph.D., National Institute on Drug Abuse*

Panelists: *R. Andrew Chambers, M.D., Indiana University School of Medicine*
Athina Markou, Ph.D., Scripps Research Institute
Jean King, Ph.D., University of Massachusetts Medical School
Jenny L. Wiley, Ph.D., Virginia Commonwealth University
William A. Carlezon, Ph.D., Harvard Medical School

3:30 – 3:45 p.m.

Break

3:45 – 5:30 p.m.

PANEL 2 (continued)

Listing and prioritizing areas of needed research

6:00 p.m.

Group Dinner (self-pay)

Tuesday, April 11, 2006

8:30 – 10:45 a.m.

PANEL 3

Methods and models: Identify disciplines and multidisciplinary cooperation that can best address questions of comorbidity—e.g., genetics, nosology, imaging, pharmacology, and new methods to develop animal models. Discuss the advantages and disadvantages of research methods and models for human, animal, and translational research.

Moderator: *Susan Volman, Ph.D., National Institute on Drug Abuse*

Panelists: *Thomas J. Crowley, M.D., University of Colorado Health Sciences Center*
Sherry Leonard, Ph.D., University of Colorado Health Sciences Center
Carlos A. Bolaños, Ph.D., Florida State University
James I. Koenig, Ph.D., University of Maryland School of Medicine
Mark A. Geyer, Ph.D., University of California, San Diego

10:45 – 11:15 a.m.

Break

11:15 a.m. – 12:30 p.m.

SUMMARY AND RECOMMENDATIONS

12:30 p.m.

Adjournment